Study of avastin and tofacitinib for skin amyloidosis
Part of Skin clinical trials.
This trial looks at people with primary cutaneous amyloidosis who have been treated with Avastin Capsules or Tofacitinib Citrate. It aims to track how well these medications work and if they are safe over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and do not have hepatitis B, tuberculosis, or other major health conditions.
- You have been diagnosed with primary cutaneous amyloidosis, macular amyloidosis, or lichen amyloidosis.
- You have visited the clinic for this condition at least 4 times.
- Your medical records show you have taken Avastin Capsules and/or Tofacitinib Citrate.
- You are not currently using other immune-suppressing drugs or biologics (like steroids or methotrexate).
- You do not have nodular or systemic amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether stapokibart (an investigational biologic) can reduce skin symptoms of primary cutaneous amyloidosis, a condition that causes itchy, discolored patches on the skin. It aims to see if the drug is safe and effective for people whose current treatments haven't worked well enough.
This trial tests whether the drug tofacitinib can help people with ALS by calming an overactive immune system. You’ll need a genetic test to see if your immune profile matches what the study is looking for.
This trial is testing a cream called tofacitinib (a type of medicine that helps calm the immune system) for people with early-stage cutaneous T-cell lymphoma (CTCL). The goal is to see if it helps shrink or control the skin lesions safely.
This trial uses a special PET/CT scan to see if a radioactive tracer can measure changes in amyloid buildup in people with CAPS who have developed a skin reaction to anakinra. It may help doctors understand how the disease is affecting your organs.
This trial tests whether adding the drug tofacitinib to standard treatment helps reduce symptoms of oral lichen planus, a chronic inflammatory mouth condition. It is for people with moderate to severe disease who have not taken certain immune-suppressing medicines recently.
This trial tests whether tofacitinib, a pill that calms the immune system, can help people whose heart inflammation caused by cancer immunotherapy (called ICI) is not improving with steroid treatment. It may offer a new option for those with this rare but serious side effect.
Hear when a new Primary Cutaneous Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.